TY - JOUR
T1 - Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
AU - Hasselbalch, Hans C.
PY - 2014/4
Y1 - 2014/4
N2 - Chronic inflammation is suggested to contribute to the Philadelphia- chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, renal, metabolic, skeletal, autoimmune, and chronic inflammatory diseases. This review describes the comorbidities associated with MPNs and the potential impact of early intervention with anti-inflammatory and/or immunomodulatory agents such as JAK-inhibitors, statins, and IFN-α to inhibit cancer progression and reduce MPN-associated comorbidity impact. Early intervention may yield a subset of patients who achieve minimal residual disease, thereby likely reducing the comorbidity burden and improving the cost-effective socioeconomic profile.
AB - Chronic inflammation is suggested to contribute to the Philadelphia- chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic. The MPN population has a substantial comorbidity burden, including cerebral, cardiovascular, pulmonary, abdominal, renal, metabolic, skeletal, autoimmune, and chronic inflammatory diseases. This review describes the comorbidities associated with MPNs and the potential impact of early intervention with anti-inflammatory and/or immunomodulatory agents such as JAK-inhibitors, statins, and IFN-α to inhibit cancer progression and reduce MPN-associated comorbidity impact. Early intervention may yield a subset of patients who achieve minimal residual disease, thereby likely reducing the comorbidity burden and improving the cost-effective socioeconomic profile.
KW - Chronic inflammation
KW - comorbidities
KW - essential thrombocythemia
KW - interferon-a2
KW - JAK-inhibitor
KW - myelofibrosis
KW - polycythemia vera
KW - socioeconomic profile
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=84896384320&partnerID=8YFLogxK
U2 - 10.1586/17474086.2013.876356
DO - 10.1586/17474086.2013.876356
M3 - Review
C2 - 24524202
AN - SCOPUS:84896384320
VL - 7
SP - 203
EP - 216
JO - Expert Review of Hematology
JF - Expert Review of Hematology
SN - 1747-4086
IS - 2
ER -